Yahoo Finance • last year

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universa... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Immuneering Corporation (NASDAQ: IMRX) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Immuneering Corporation (NASDAQ: IMRX) on behalf of the company’s investors. Since October 2021, shares of Immuneering’s common stock ha... Full story

Yahoo Finance • last year

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development plan for IMM-1-104, Phase 2a portion of stu... Full story

Yahoo Finance • last year

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RA... Full story

Yahoo Finance • last year

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS th... Full story

Yahoo Finance • last year

Immuneering to Present at the Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS t... Full story

Yahoo Finance • 2 years ago

Immuneering Announces $30 Million Underwritten Offering

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a... Full story

Yahoo Finance • 2 years ago

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed... Full story

Yahoo Finance • 2 years ago

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS t... Full story

Yahoo Finance • 2 years ago

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS t... Full story

Yahoo Finance • 2 years ago

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS t... Full story

Yahoo Finance • 2 years ago

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

Demonstrates ability to identify patient populations that may benefit from IMM-1-104 treatment Biomarker discovery and clinical translation supports patient selection in ongoing Phase 1/2a clinical trial with IMM-1-104 in patients with ad... Full story

Yahoo Finance • 2 years ago

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

First patient dosed in Phase 1/2a clinical trial of IMM-1-104 in advanced solid tumors with any RAS mutation Provides debut guidance for IMM-1-104 program: initial Phase 1 PK and safety data expected in mid-2023,initial Phase 1 PD modelin... Full story

Yahoo Finance • 2 years ago

Immuneering Announces Participation in March Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS th... Full story

Yahoo Finance • 2 years ago

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS th... Full story

Yahoo Finance • 2 years ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

IMM-1-104 being tested in first all-comers RAS clinical trial believed to be conducted to date First patient dosed follows swiftly from IND clearance at the end of September CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Immuneeri... Full story

Yahoo Finance • 2 years ago

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Recruiting has Commenced for Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (NCT05585320), with the First Patient Expected to be Dosed this Quarter Shares Promising Preclinical Data on Second Program IM... Full story

Yahoo Finance • 2 years ago

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

IMM-6-415 Shows Preclinical Activity as a Single Agent in RAF and RAS Mutant Tumors and Enhances PD1 and CTLA4 Checkpoint Blockade IMM-6-415 is Designed to Provide Deep Cyclic Inhibition of the MAPK Pathway with an Accelerated Cadence Rel... Full story

Yahoo Finance • 2 years ago

Immuneering Appoints Leah R. Neufeld as Chief People Officer

CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activ... Full story

Yahoo Finance • 2 years ago

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

CAMBRIDGE, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations... Full story